It is widely accepted that supplementation with folic acid, a B vitamin, reduces the risk of neural tube defects (NTDs). This case-control study tested the hypothesis that multivitamins reduce risks of selected birth defects other than NTDs. Infants with and without birth defects and aborted fetuses with birth defects were ascertained in the greater metropolitan areas of Boston, Philadelphia, and Toronto during 1993-1996. Mothers were interviewed within 6 months after delivery about a variety of factors, including details on vitamin use. Eight case groups were included: cleft lip with or without cleft palate, cleft palate only, conotruncal defects, ventricular septal defects, urinary tract defects, limb reduction defects, congenital hydrocephaly, and pyloric stenosis (n's ranged from 31 to 186). Controls were 521 infants without birth defects (nonmalformed controls) and 442 infants with defects other than those of the cases (malformed controls). Daily multivitamin supplementation was evaluated according to gestational timing categories, including periconceptional use (28 days before through 28 days after the last menstrual period). Odds ratios (ORs) below 1.0 were observed for all case groups except cardiac defects, regardless of control type. For periconceptional use, ORs with 95% confidence intervals that excluded 1.0 were estimated for limb reduction defects using both nonmalformed controls (OR = 0.3) and malformed controls (OR = 0.2) and for urinary tract defects using both nonmalformed controls (OR = 0.6) and malformed controls (OR = 0.5). Statistically significant ORs for use that began after the periconceptional period were observed for cleft palate only and urinary tract defects. These data support the hypothesis that periconceptional vitamin supplementation may extend benefits beyond a reduction in NTD risk. However, other than folic acid's protecting against NTDs, it is not clear what nutrient or combination of nutrients might affect risk of other specific defects. Am J Epidemiol 1999;150:675-82.
There has been long-standing interest in the relation between vitamin supplementation and the risk of birth defects. In particular, the well documented reduction in neural tube defect risk induced by folic acid has prompted widespread health advisories promoting daily supplementation among all women of childbearing age (1, 2) . Recently, reports have also suggested that multivitamin supplementation before pregnancy or early in pregnancy reduces the risks of other specific congenital malformations, including defects of the lip and palate (3, 4) , heart (5-8), limbs (5, 7, 9) , urinary tract (5, 10), brain (5) , and pylorus muscle (5) . The present study tested the hypothesis that periconceptional multivitamin supplementation reduces the risks of these specific birth defects, using data collected in a large case-control study.
MATERIALS AND METHODS
The data were collected by the Boston University Slone Epidemiology Unit Birth Defects Study in the greater metropolitan areas of Boston, Massachusetts; Philadelphia, Pennsylvania; and Toronto, Ontario, Canada (11) . Infants with major malformations identified by 5 months of age were ascertained in birth hospitals and in tertiary care hospitals, as were women whose pregnancies had been terminated because of a malformed fetus. Beginning in 1993, a random sample of nonmalformed infants was also ascertained from birth hospitals. Because of staffing limitations, not all ascertained subjects were approached for interview. Each month, interview subjects were selected to include: 1) those with any of approximately 10 "priority" diagnoses (a list that reflected the then-current research interests of the program); 2) an approximate 25 percent random sample of ascertained nonmalformed subjects; and 3) subjects with malformations other than the "priority" diagnoses who resided in the same general geographic area as subjects selected under points 1 and 2. Because interviews were conducted in person, most often in the subject's home, the third criterion served to maximize interview efficiency by minimizing travel time.
The questionnaire was administered by a study nurse no more than 6 months after delivery. Questions were asked about demographic, reproductive, and medical factors; medication, alcohol, and cigarette use; and dietary intake. The product name, starting and stopping dates, and frequency of use were recorded for each vitamin supplement that was taken at any time from 2 months before the last menstrual period through the end of the pregnancy. The present analysis includes data from interviews conducted between 1993 and 1996.
For the present study, eight case groups were identified based on defects that had been reported in the literature (3-10) as possibly being inversely associated with multivitamin use (table 1) . The case groups excluded subjects with any neural tube defect, known chromosomal anomaly, or Mendelian inherited disorder. Of the case defect groups, only conotruncal defects and limb reduction defects were considered Birth Defect Study "priority" diagnoses for interview selection purposes as described above. Controls were 521 infants with no major structural malformations (nonmalformed controls). We also created a secondary control group comprising the 442 subjects with major malformations, after excluding infants with neural tube defects and the eight case defects, to address the possibility of recall bias (malformed controls). The distribution of malformations in the malformed control group was as follows: genital defects, 16 percent; talipes varus or valgus defects, 14 percent; diaphragmatic hernia, 10 percent; gastroschisis, 9 percent; craniosynostosis, 7 percent; intestinal atresia, 6 percent; and various other defects, 38 percent. Gastroschisis (1993) (1994) and craniosynostosis were Birth Defect Study "priority" diagnoses for interview selection purposes as described above.
Mothers who resided within our geographically defined catchment areas (approximately a 2-hour drive from either Boston, Philadelphia, or Toronto), who spoke English, and whose physicians provided consent for us to contact them were eligible for inclusion. The physicians of 7 percent of malformed cases, 3 percent of nonmalformed controls, and 8 percent of malformed controls refused participation. Because more subjects were ascertained than could be interviewed and because we set a limit that interviews had to be completed within 6 months after delivery, the mothers of 55 percent of ascertained cases, 72 percent of ascertained nonmalformed controls, and 57 percent of ascertained malformed control subjects were not asked to participate. Of those who were asked to participate, the mothers of 66 percent of cases, 65 percent of nonmalformed controls, and 66 percent of malformed controls agreed to be interviewed.
Multivitamin supplementation was defined as daily use of a supplement that contained at least two watersoluble vitamins and at least two fat-soluble vitamins. Supplementation was categorized by the beginning of first use, according to lunar month of pregnancy (28-day months beginning with the last menstrual period), as follows: the month before the last menstrual period through lunar month 1 (pre-LMl); lunar month 2 (LM2); lunar month 3 (LM3); and lunar month 4 (LM4). For each case group, odds ratios were estimated for developmentally appropriate gestational timing categories of supplementation. Specifically, conotruncal defects and ventricular septal defects develop before mid-LM2, so odds ratios were estimated for the pre-LMl and LM2 categories, with no use during those time periods designated as the reference categories. Cleft lip with or without cleft palate (CL/P) and Umb reduction defects develop by the end of LM3, so odds ratios were estimated for pre-LMl, LM2, and LM3, with no use in those time periods being defined as the reference categories. For the defects for which developmental timing is either not known (pyloric stenosis), varies across specific defects within the group (urinary tract defects), or occurs later in gestation (cleft palate only, hydrocephaly), preLMl, LM2, LM3, and LM4 were examined, with no use in those time periods being defined as the reference categories. In addition, an "etiologically relevant" summary measure was estimated for each defect by combining the appropriate timing categories (e.g., for CUP, use beginning at any time between pre-LMl and LM3, and for cleft palate alone, use beginning at any time between pre-LMl and LM4). Odds ratios were not estimated if there were fewer than four exposed subjects in a timing category.
Multivariate-adjusted odds ratios and 95 percent confidence intervals were estimated using unconditional logistic regression models (12) . Factors found to be related to multivitamin use were included in the multivariate models: maternal age (<20,20-24,25-29, and >30 years), maternal education (<12, 12, 13-15, and >16 years), maternal race (White/Nonwhite), planned pregnancy (yes/no), nausea and vomiting during the first lunar month of pregnancy (yes/no), and geographic center (Boston, Philadelphia, and Toronto).
RESULTS
To assess possible demographic differences among case and control participants and nonparticipants, we examined community-level median family income. Zip code information for US mothers was linked to 1990 US Census data on median family income (13) . The distributions of income categories (<$25,000, $25,000-$34,999, $35,000-$44,999, $45,000-$54,999, $55,000-$64,999, and >$65,000 per year) were similar (data not shown) for interviewed and noninterviewed mothers of cases, nonmalformed controls, and malformed controls, with one exception. Among interviewed mothers, the lowest category of zip code-linked income (<$25,0O0) was prevalent in 3 percent, 2 percent, and 4 percent of cases, nonmalformed controls, and malformed controls, respectively. The corresponding prevalences for noninterviewed mothers were 9 percent, 9 percent, and 10 percent, respectively.
The distribution of supplement use according to gestational timing is shown in table 2 for mothers of cases and controls. The prevalence of no use in the first 4 lunar months of pregnancy ranged from 11 percent to 26 percent. Across all case and control groups, the majority of women began supplementation during preLMl or LM2, followed by declines in the prevalence of first use during LM3 and LM4. Women who used supplements less than daily did so in a variety of patterns across the early months of gestation, but few were less-than-daily users throughout the 5-lunarmonth period under study. For example, some women began using prenatal vitamins during the first months of pregnancy, but took them infrequently because of nausea; they then became daily users later in the first trimester when the nausea had subsided. Because our analysis attempted to examine the effects of gestational timing by month of first use, it was difficult to categorize the erratic patterns of less-than-daily users. Therefore, they were excluded from risk estimation.
Odds ratio estimates (and 95 percent confidence intervals) are presented in table 3 for case groups, with nonmalformed controls used as the reference group. Risk estimates below 1.0 were observed for all case groups except cardiac defects. Statistically significant odds ratios were observed for cleft palate only and first use in LM2; for limb reduction defects and first use in pre-LMl; and for urinary tract defects and first use in LM2. In contrast, odds ratios for both conotruncal defects and ventricular septal defects were close to 1.0. Conotruncal defects were further divided into specific defects (data not shown): Among 49 cases with tetralogy of Fallot, the odds ratio was 1.7 (95 percent confidence interval (Cl): 0.8, 3.6) for pre-LM2 supplementation; among 63 cases with transposition of the great arteries, the corresponding estimate was 0.9 (95 percent Cl: 0.5, 1.7). When obstructive urinary tract defects were examined (data not shown), the odds ratio was 0.5 (95 percent Cl: 0.3, 1.0) for pre-LM4.
The possibility of differential maternal recall of multivitamin use between malformed and nonmalformed subjects prompted us to also estimate risks using malformed controls. Table 4 presents odds ratio estimates for each case group and the relevant supplement timing categories. Estimates were similar to those derived using the nonmalformed control group (table 3) . For tetralogy of Fallot, the odds ratio was 1.4 (95 percent Cl: 0.7, 2.8) for pre-LM2 use; the corresponding estimate for transposition of the great arteries was 0.9 (95 percent Cl: 0.5, 1.6). The obstructive urinary tract defect risk estimate for pre-LM4 use was 0.5 (95 percent Cl: 0.3, 0.9).
Twenty-one case women and eight malformed control women, but no nonmalformed control women, had undergone a pregnancy termination. Because these women were interviewed approximately 4 months • Pre-LM2 for conotruncal and ventricular septal defects; pre-LM3 for cleft lip with or without cleft palate and Dmb reduction defects; pre-LM4 for cleft palate only, urinary tract defect, hydrocephaly, and pytoric stenosis, t OR, odds ratio; Cl, confidence interval. closer to the time of conception than were women who delivered near term, and because the diagnoses in approximately 60 percent of the terminations were not confirmed by autopsy, we reestimated odds ratios after excluding these subjects. There were no appreciable changes in risk estimates (data not shown).
DISCUSSION
In this study, we examined risks of congenital defects other than neural tube defects that were previously hypothesized to be reduced by the use of multivitamin supplements. The present data confirm reductions in the risks of cleft palate alone, limb reduction defects, and urinary tract defects. Only moderate and statistically nonsignificant reductions in risk were observed for CL/P, hydrocephaly, and pyloric stenosis, and no reductions in risk were observed for conotruncal defects or ventricular septal defects.
Since multivitamins typically contain folk acid, multivitamin supplementation during the periconceptional period (pre-LMl) reflects behavior that is consistent with the US Public Health Service recommendation (1) that all women of childbearing age ingest 400 (ig of folic acid daily to reduce the risk of neural tube defects. In the present study, such supplementation appeared to reduce the risks of limb reduction defects and urinary tract defects, and possibly the risks of CL/P, cleft palate alone, hydrocephaly, and pyloric stenosis as well, though estimates for the latter four defects were not statistically significant. In addition, supplementation that began after LM1 (after pregnancy was clinically recognizable) was associated with reduced risks of cleft palate alone and urinary tract defects. Furthermore, use that began in LM3 was associated with a reduction in pyloric stenosis risk that was of borderline statistical significance.
For neural tube defects, many studies have shown a multivitamin effect (1); however, it is widely held that it is the folic acid component that affords the benefit, because of a randomized trial conducted by the Medical Research Council (14) which showed a 60 percent reduction in risk of neural tube defects among women using folic acid supplements compared with women using multivitamins containing no folic acid. For defects other than neural tube defects, it is not clear what specific nutrient or combinations of nutrients might affect risk; in fact, it/they may vary from one malformation to another. Most vitamin supplements include more than eight water-soluble vitamins and three fat-soluble vitamins and at least four minerals or trace elements, and their overlap precluded us from identifying independent effects. In the present study, approximately 90 percent of nonprenatal multivitamin preparations and 100 percent of prenatal multivitamin preparations included folic acid.
Earlier reports on supplementation and reduced risks of malformations (other than neural tube defects) included a variety of study designs and definitions of supplementation (3) (4) (5) (15) (16) (17) (18) . The present observations support some but not all of those findings. For oral clefts, previous studies have reported inconsistent findings, including a reduced risk of CL/P (15); a reduced risk of cleft palate alone but not of CL/P (5, 16); a reduced risk of CL/P but not of cleft palate alone (17) ; reduced risks of both CL/P and cleft palate alone (3, 4) ; and no association for both CL/P and cleft palate alone (18) . Differences in study design do not completely explain the inconsistencies in findings across the previous studies and the present data. One study conducted by our group using earlier data (18) showed no association, but we had included in the malformed control group some of the case defects found in the present study to be inversely associated with vitamin use. The inclusion of those defect groups as controls resulted in similar rates of supplementation between case and control groups, but this does not fully account for the earlier null finding.
In the present study, it appears that gestational timing may be an important factor for clefts: The greatest reduction in risk of CL/P (based on the malformed control group) was estimated for periconceptional use, whereas the greatest reduction in risk of cleft palate alone was found for first use in LM2 (using either control group). These findings are consistent with the fact that CL/P develops approximately 3 weeks earlier than cleft palate alone.
A randomized trial that treated approximately equal numbers of women with either multivitamins or trace elements showed the risk of ventricular septal defect to be lower in the vitamin-treated group (5). For conotruncal defects, risk was found to be reduced in two case-control studies and one randomized trial, but the effect was primarily observed for transposition of the great arteries (5, 6) and/or tetralogy of Fallot (5-7). In contrast, our data are consistent with those of a large case-control study (8) which showed no association between preconceptional multivitamin supplementation and risks of transposition of the great arteries and other conotruncal defects. Differences in study design offer no clear explanation for the discordant results. Furthermore, the distribution of defects within the conotruncal group in the present study was similar to that reported in the population-based studies (6) (7) (8) For limb reduction defects, our findings are generally consistent with those of earlier reports which suggested reductions in risk for periconceptional or early first trimester use (5, 7, 10) , with the greatest effect being evident for periconceptional use (5, 10) . Two of the earlier studies divided limb reduction defects by type of limb deficiency; one found that the effect was confined to limb reduction defects other than longitudinal deficiencies (10) , while the other found that the effect was confined to limb reduction defects other than transverse deficiencies (7). Unfortunately, there were too few limb reduction defects in the present study to examine these subtypes.
A case-control study of urinary tract defects and nonmalformed controls (9) found statistically significant reductions in risk associated with supplementation before, during, and after the first trimester. In addition, the previously described randomized trial (5) observed one case of obstructive urinary tract defects and no cases of renal agenesis in the supplemented group, as compared with three cases of the former and two cases of the latter in the nonsupplemented group. The present study confirmed these findings in that risks for urinary tract defects overall and for the subgroup of obstructive defects were generally below 1.0 for all timing categories and were significantly reduced for pre-LMl and LM2 supplementation. There were too few cases of renal agenesis in the present study to examine them separately.
In the same randomized trial (5), fewer cases of congenital hydrocephalus and pyloric stenosis were observed in the supplemented group than in the nonsupplemented group. We estimated some risks of congenital hydrocephaly to be below the null value, but we found no statistically significant reductions in risk or informative patterns of risk across gestational timing categories. For pyloric stenosis, we found that periconceptional use or first use in LM2 did not reduce risk, but later first trimester use did. The possible benefit of relatively late exposure is consistent with the randomized trial in that women in the supplemented group were started on multivitamins before conception and use continued at least through the first trimester. Furthermore, the findings are of interest in that the gestational timing of pyloric stenosis is not known; but the defect is thought to result from a functional disorder of the pyloric sphincter, which suggests that it may arise later in gestation than most other congenital defects (19) .
For the overall data, we considered possible sources of error. First, we attempted to reduce the potential for information bias with rigorous data collection, including use of a standardized questionnaire administered within 6 months after the date of delivery. Although the possibility of random misclassification of supplementation information still exists, we believe it would not have a strong influence on the findings, because our estimates of periconceptional prevalence for control mothers are similar to recently published rates (3, 20) .
Differential misclassification (due either to maternal reporting or to interviewer bias) is another possibility, but it appears to be unlikely given that risk estimates based on nonmalformed controls were remarkably similar to those based on malformed controls. In addition, supplementation was reported to reduce the risks of many of the same defects in a randomized controlled trial (5) in which recall bias was not an issue.
There is a possibility that bias may have been introduced because subject ascertainment was not population-based, not all ascertained subjects were asked to participate, and approximately one third of mothers who were asked to participate refused to be interviewed. If incomplete enrollment were conditional on multivitamin use and such enrollment differed between cases and controls, selection bias would occur. However, the observed findings are not likely to be due to selection bias, for several reasons. First, the network of ascertainment hospitals included the full range of urban, suburban, and rural communities. Second, our use of general geographic proximity as the basis for choosing non-"priority" subjects had little effect on the distribution of socioeconomic status in each group, because the geographic areas were large and included communities representing all socioeconomic strata. Third, the similar distributions of zip code-linked median family income for US study subjects suggest that interviewed mothers may have had a higher socideconomic status than noninterviewed mothers; but there was little difference in such status between cases and controls, which reduces concerns about biased risk estimation. Study procedures were the same at our Toronto center as at the other two centers, so the US zip code findings can most likely be extrapolated to our Canadian study subjects.
Selection bias might have been introduced by the inclusion of multivitamin-associated defect subgroups. The wide range of defects among the malformed controls and the similarity in supplementation rates between the two control groups suggest that selection bias was not introduced by the inclusion of these subgroups.
Finally, residual confounding is a possibility. We controlled for several factors that are associated with multivitamin supplementation, but there may be other differences between women who take supplements routinely or early in pregnancy and women who start taking them very late in pregnancy or do not take them at all. If those differing factors affect risks of any of the case or control defects, observed estimates may have been confounded.
Studies carried out to date suggest that the benefits of periconceptional multivitamin supplementation may extend beyond a reduction in the risk of neural tube defects. If such supplementation does in fact reduce the risk of specific birth defects, the current public health recommendation that all women of childbearing age ingest 400 |i.g of folic acid daily (1) may need to be broadened to include a wider range of nutrients. Exactly which nutrients should be taken is not clear, but multivitamin supplements containing 400 | Xg of folic acid may offer greater benefit than folic acid supplements alone.
